A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics

Pharmaceutical Research

Volumn 15, Issue 8, 1998, Pages 1174-1181

  Camenisch, Gian P ^a   Wang, Wei ^b   Wang, Binghe ^b   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Caco 2 cells; Chemical and enzymatic stability; Drug delivery; Esterase sensitive prodrugs; Membrane permeability; Peptidomimetic

Indexed keywords

PRODRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSPORT KINETICS;

ANIMALS; CACO-2 CELLS; COUMARINS; DRUG STABILITY; ESTERS; HUMANS; MALE; MOLECULAR MIMICRY; OLIGOPEPTIDES; PERMEABILITY; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031666038     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011975404789     Document Type: Article

References (39)

1. G. D. Hartman, M. S. Egbertson, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. J. Lynch, G. Zhang, C. T. Chang, and R. J. Gould. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35:4640-4642 (1992).
2. D. R. Philips, I. F. Charo, L. V. Parise, and L. A. Fitzgerald. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843 (1988).
3. J. Zablocki, N. Nicholson, and B. Taite. Selection of an orally active glycoprotein IIb/IIIa receptor antagonist for clinical trials. Thromb. Haemostas. 69:1244 (1993).
4. H. U. Stilz, B. Jablonka, M. Just, J. Knolle, E. F. Paulus, and G. Zoller. Discovery of an orally active non-peptide fibrinogen receptor antagonist. J. Med. Chem. 39:2118-2122 (1996).
5. V. Austel, F. Himmelsbach, and T. Muller. Nonpeptidic fibrinogen receptor antagonists. Drugs of the Future 19:757-764 (1984).
6. J. A. Zablocki, M. Miyano, R. B. Garland, D. Pireh, L. Schretzman, S. N. Rao, R. J. Lindmark, S. G. Panzer-Knodle, N. S. Nicholson, B. B. Taite, A. K. Salyers, L. W. King, J. G. Campion, and L. P. Geigen. Potent in vitro and in vivo inhibitors of platelet aggregation based on the Arg-Gly-Asp sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor. J. Med. Chem. 36:1813-1819 (1993).
7. J. S. Barrett, G. Murphy, K. Peerlinck, I. DeLepeleire, R. J. Gould, D. Panbianco, E. Hand, H. Deckmyn, J. Vermylen, and J. Arnout. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 56:377-388 (1994).
8. S. Vickers, C. A. Duncan, A. S. Yuan, and K. P. Vyas. Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. Drug Metab. Dispos. 22:631-636 (1994).
9. T. Prueksaritanont, L. M. Gorham, J. D. Ellis, C. Fernandez-Metzler, P. Deluna, J. R. Gehret, K. L. Strong, J. H. Hochman, B. C. Askew, M. K. Duggan, J. D. Gilbert, J. H. Lin, and K. P. Vyas. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies. Drug Metab. Dispos. 24:1263-1271 (1996).
10. T. Prueksaritanont, L. M. Gorham, J. A. Naue, T. G. Hamill, B. C. Askew, and K. P. Vyas. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Drug Metab. Dispos. 25:355-361 (1997).
11. J. S. Barrett, R. J. Gould, J. D. Ellis, M. M. Holahan, M. T. Stranieri, J. J. Lynch, Jr., G. D. Hartman, N. Ihle, M. Duggan, O. A. Moreno, and A. D. Theoharides. Pharmacokinetics and pharmacodynamics of L-303,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm. Res. 11:426-431 (1994).
12. N. B. Modi, S. A. Baughman, B. D. Paasch, A. Celnitur, and S. Y. Smith. Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIb/IIIa antagonist, in rats and dogs. J. Cardiovasc. Pharmacol. 25:888-897 (1995).
13. J. H. Hutchinson, J. J. Cook, K. M. Brashear, M. J. Breslin, J. D. Glass, R. J. Gould, W. Halczenko, M. A. Holahan, R. J. Lynch, G. R. Sitko, M. T. Stranieri, and G. D. Hartman. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1(1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. J. Med. Chem. 39:4583-4591 (1996).
14. T. Weller, L. Alig, M. Beresini, B. Blackburn, S. Bunting, P. Hadvary, M. Hürzeler Müller, D. Knopp, B. Levet-Trafit, M. Terry Lipari, N. B. Modi, M. Müller, C. J. Refino, M. Schmitt, P. Schönholzer, S. Weiss, and B. Steiner. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. 39:3139-3147 (1996).
15. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. S. Stella, and R. T. Borchardt. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Disc. Today 2:22-29 (1997).
16. B. Wang, S. Gangwar, G. M. Pauletti, T. J. Siahaan, and R. T. Borchardt. Synthesis of a novel esterase-sensitive cyclic prodrug system for peptides that utilizes a trimethyl lock-facilitated lactonization reaction. J. Org. Chem. 62:1363-1367 (1997).
17. G. M. Pauletti, S. Gangwar, F. W. Okumu, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1615-1623 (1996).
18. G. M. Pauletti, S. Gangwar, B. Wang, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of a phenylpropionic acid promoiety in a model hexapeptide. Pharm. Res. 14:11-17 (1997).
19. B. Wang, W. Wang, and H. Zhang. Chemical feasibility studies of a potential coumarin-based prodrug system. Bioorg. Med. Chem. Lett. 6:945-950 (1996).
20. B. Wang, W. Wang, H. Zhang, D. Shan, and T. D. Smith. Coumarin-based prodrugs. 2. Synthesis and bioreversibility studies of an esterase-sensitive cyclic prodrug of DADLE, an opioid peptide. Bioorg. Med. Chem. Lett. 6:2823-2826 (1996).
21. B. Wang, W. Wang, G. Camenisch, J. Elmo, H. Zhang, and R. T. Borchardt. Coumarin-based prodrugs 4. Synthesis and evaluation of esterase-sensitive cyclic prodrugs of antithrombotic RGD analogs. Bioorg. Med. Chem.: submitted (1998).
22. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Biochemical, histological and physicochemical characterization of human adenocarcinoma cells (Caco-2) as a model system for studying mucosal transport and metabolism of drugs. Gastroenterology 96:736-749 (1989).
23. R. Oliyai. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Delivery Rev. 19:275-286 (1996).
24. W. N. Aldrige. Serum esterases. 1. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, proprionate and butyrate, and a method for their determination. Biochem. J. 53:110-117 (1953).
25. D. S. Auld and B. Holmquist. Carboxypeptidase A. Differences in the mechanism of ester and peptide hydrolysis. Biochemistry 13:4355-4361 (1974).
26. G. M. Pauletti, S. Gangwar, G. T. Knipp, M. M. Nenikar, F. W. Okumu, K. Tamura, T. J. Siahaan, and R. T. Borchardt. Structural requirements for intestinal absorption of peptide drugs. J. Controlled Rel. 41:3-17 (1996).
27. P. S. Burton, R. A. Conradi, A. R. Hilgers, and N. F. H. Ho. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:760-765 (1993).
28. A. Tsuji, and I. Tamai. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:963-977 (1996).
29. H. Van de Waterbeemd, G. Camenisch, G. Folkers, and O. A. Raevsky. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant. Struct. Act. Relat. 15:480-490 (1996).
30. G. Camenisch, H. Van de Waterbeemd, and G. Folkers. Review on theoretical passive drug absorption models. Pharm. Acta Helv. 71:309-327 (1996).
31. P. Artursson. Cell cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst. 8:305-330 (1991).
32. S. Gan, C. Eads, T. Niederer, A. Bridgers, S. Yanni, P. H. Hsyu, F. J. Pritchard, and D. Thakker. Use of Caco-2 as an in-vitro intestinal absorption and metabolism model. Drug Develop. Ind. Pharm. 20:615-631 (1994).
33. K. M. Hillgren, A. Kato, and R. T. Borchardt. In vitro systems for studying intestinal drug absorption. Med. Res. Rev. 15:83-109 (1995).
34. S. Ong, H. Liu, X. Qiu, G. Bhat, and Ch. Pidgeon. Membrane partition coefficients chromatographically measured using immobilized artificial surfaces. Anal. Chem. 67:755-762 (1995).
35. F. Barbato, M. La Rotonda, and F. Quaglia. Chromatographic indices determined on an immobilized artificial membrane (IAM) column as descriptors of lipophilic and polar interactions of 4-phenyldihydropyridine calcium-channel blockers with biomembranes. Eur. J. Med. Chem. 31:311-318 (1996).
36. N. El Tayar, H. Van de Waterbeemd, and B. Testa. Lipophilicity measurements of protonated basic compounds by reversed-phased high-performance liquid chromatography. 1. Relationship between capacity factors and the methanol concentration in methanol-water eluents. J. Chromatogr. 320:293-304 (1985).
37. N. El Tayar, H. Van de Waterbeemd, and B. Testa. Lipophilicity measurements of protonated basic compounds by reversed-phased high-performance liquid chromatography. II. Procedure for the determination of a lipophilic index measured by reversed-phased high-performance liquid chromatography. J. Chromatogr. 320:305-312 (1985).
38. A. R. Hilgers, R. A. Conradi, and P. S. Burton. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7:902-909 (1990).
39. P. Annaert, R. Kinget, L. Naesens, E. de Clerq, and P. Augustijns. Transport, uptake, and metabolism of the bis(pivaloxymethyl)-ester prodrug of 9-(2-phosphonyl-methoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:492-496 (1995).